Idinvest et al. back Pathoquest with €3.8m

The fresh funding will be used to finance the commencement of a clinical study for diagnosing infectious diseases through high-output sequencing, a cloud computing system developed by Pathoquest.

Aurinvest invested in the series-B round for the company via its €17m Aurinvest Capital 3 fund. KLS invested via its Kurma Biofund vehicle, which held its first close in November 2009 on €50m.

Previous funding
In 2011, Pathoquest received €2m in a series-A funding round from KLS.

Company
Founded in 2010, Pathoquest is a spin-off of the Pasteur Institute and the National Veterinary School of Alfort. The company, which is based in Paris, develops data analysis solutions for outbreaks of infectious diseases. It does so by using a high-output sequencing system that is deployed via a cloud-based software-as-a-service solution.

People
Marc Eliot is the president and scientific director of Pathoquest. Thierry Laugel is a managing partner at KLS, while Michel Demont is the president of Aurinvest.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• IDInvest Partners (AGF Private Equity)
• France